ECSP066452A - Métodos para el tratamiento del cáncer con inhibidores de hdac - Google Patents
Métodos para el tratamiento del cáncer con inhibidores de hdacInfo
- Publication number
- ECSP066452A ECSP066452A EC2006006452A ECSP066452A ECSP066452A EC SP066452 A ECSP066452 A EC SP066452A EC 2006006452 A EC2006006452 A EC 2006006452A EC SP066452 A ECSP066452 A EC SP066452A EC SP066452 A ECSP066452 A EC SP066452A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- hdac inhibitors
- pharmaceutical compositions
- present
- mesothelioma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Prostheses (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Electrotherapy Devices (AREA)
Abstract
La presente invención se refiere a métodos para el tratamiento de cánceres, por ej., mesotelioma o linfoma. Más específicamente, la presente invención se refiere a métodos para el tratamiento del mesotelioma o del linfoma difuso de células B grandes (DLBCL, por sus siglas en inglés), por medio de la administración de composiciones farmacéuticas que comprenden inhibidores de HDAC, por ej., ácido hidroxámico suberoilanilida (SAHA, por sus siglas en inglés). Las formulaciones orales de las composiciones farmacéuticas tienen perfiles farmacocinéticos favorables, tales como biodisponibilidad alta, y sorprendentemente generan altos niveles sanguíneos de los compuestos activos durante un período prolongado. La presente invención además provee un régimen de dosificación diaria seguro de estas composiciones farmacéuticas, el cual es fácil de seguir y resulta en una cantidad terapéuticamente efectiva de los inhibidores de HDAC in vivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/650,025 US7148257B2 (en) | 2002-03-04 | 2003-08-26 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US10/665,079 US20040127523A1 (en) | 2002-03-04 | 2003-09-16 | Methods of treating cancer with HDAC inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066452A true ECSP066452A (es) | 2006-09-18 |
Family
ID=34556614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006452A ECSP066452A (es) | 2003-08-26 | 2006-03-23 | Métodos para el tratamiento del cáncer con inhibidores de hdac |
Country Status (23)
Country | Link |
---|---|
US (1) | US20090012175A1 (es) |
EP (2) | EP1663194B1 (es) |
JP (2) | JP4338734B2 (es) |
KR (1) | KR100924737B1 (es) |
CN (1) | CN102188415A (es) |
AT (1) | ATE462426T1 (es) |
AU (1) | AU2004266169B9 (es) |
BR (1) | BRPI0413826A (es) |
CA (1) | CA2535806C (es) |
DE (1) | DE602004026321D1 (es) |
DK (1) | DK1663194T3 (es) |
EC (1) | ECSP066452A (es) |
ES (1) | ES2345775T3 (es) |
HR (1) | HRP20060080A2 (es) |
IL (1) | IL173846A0 (es) |
MA (1) | MA28209A1 (es) |
NO (1) | NO328575B1 (es) |
NZ (2) | NZ560485A (es) |
PL (2) | PL379887A1 (es) |
PT (1) | PT1663194E (es) |
RU (1) | RU2356547C2 (es) |
SI (1) | SI1663194T1 (es) |
WO (1) | WO2005018578A2 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
NZ567758A (en) * | 2002-03-04 | 2009-07-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA) |
US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
EP1501489A4 (en) * | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
EP1613592A4 (en) * | 2003-04-01 | 2008-03-12 | Sloan Kettering Inst Cancer | HYDROXANIC ACID COMPOUNDS AND METHOD FOR THE APPLICATION |
US7901675B2 (en) * | 2004-10-13 | 2011-03-08 | U.S. Department Of Veterans Affairs | Method of using coenzyme Q10 to treat Huntington's disease |
US20060135612A1 (en) * | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
EP2522395A1 (en) | 2005-02-03 | 2012-11-14 | TopoTarget UK Limited | Combination therapies using HDAC inhibitors |
WO2006102557A2 (en) | 2005-03-22 | 2006-09-28 | The President And Fellows Of Harvard College | Treatment of protein degradation disorders |
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
DK2494969T3 (en) | 2005-05-13 | 2015-06-15 | Topotarget Uk Ltd | Pharmaceutical formulations of the HDAC inhibitors |
TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
KR20080032188A (ko) | 2005-07-14 | 2008-04-14 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
GB0518720D0 (en) * | 2005-09-14 | 2005-10-19 | Hamlet Pharma Ab | Therapeutic combination |
WO2007056243A2 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co. Inc. | Methods of treating cancers with saha and fluorouracil and other combination therapies |
AU2006311829B8 (en) * | 2005-11-04 | 2013-02-21 | Merck Sharp & Dohme Corp. | Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies |
CA2627129A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and bortezomib for treating cancer |
AU2006313517B2 (en) | 2005-11-10 | 2013-06-27 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
EP2010168B1 (en) | 2006-02-14 | 2014-04-16 | The President and Fellows of Harvard College | Histone deacetylase inhibitors |
AU2007345292B2 (en) * | 2006-02-14 | 2013-10-31 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
WO2007145704A2 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
CA2654540C (en) | 2006-05-03 | 2017-01-17 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
KR20090087013A (ko) | 2006-10-30 | 2009-08-14 | 크로마 데러퓨릭스 리미티드 | 히스톤 탈아세틸효소의 억제제로서 히드록사메이트 |
EP2086323A4 (en) * | 2006-11-03 | 2010-01-06 | Univ Maryland | METHOD OF USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA |
CA2674309A1 (en) | 2006-12-29 | 2008-07-10 | Gloucester Pharmaceuticals, Inc. | Preparation of romidepsin |
MX2010003230A (es) * | 2007-09-25 | 2010-04-07 | Topotarget Uk Ltd | Metodos para la sintesis de ciertos compuestos de acido hidroxamico. |
WO2009064300A1 (en) * | 2007-11-15 | 2009-05-22 | The Johns Hopkins University | Combinations of hdac inhibitors and cytokines/growth factors |
MX2010009642A (es) * | 2008-03-07 | 2010-09-22 | Topotarget As | Metodos de tratamiento utilizando infusion continua prolongada de belinostat. |
RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
AU2009305214B2 (en) | 2008-10-15 | 2015-06-25 | Generics [Uk] Limited | Process for the preparation of vorinostat |
CA2744448A1 (en) | 2008-11-26 | 2010-06-03 | Vinayak Gore | Polymorphs |
GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
SG187032A1 (en) | 2010-07-12 | 2013-02-28 | Celgene Corp | Romidepsin solid forms and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US8895245B2 (en) * | 2010-09-10 | 2014-11-25 | Epizyme, Inc. | Inhibitors of human EZH2 and methods of use thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
CN102846611A (zh) * | 2011-09-24 | 2013-01-02 | 复旦大学 | 斯克瑞泰Scriptaid在制备治疗创伤性脑损伤疾病药物中的用途 |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
CA2888021A1 (en) | 2012-10-15 | 2014-04-24 | Epizyme, Inc. | Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
CN103169807A (zh) * | 2013-04-11 | 2013-06-26 | 太仓市胜舟生物技术有限公司 | 一种中西组合药物在制药中的应用 |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
WO2015190700A1 (ko) * | 2014-06-11 | 2015-12-17 | 성균관대학교산학협력단 | 패혈증 예방 또는 치료용 약학적 조성물 |
CN117797149A (zh) * | 2018-11-20 | 2024-04-02 | 深圳微芯生物科技股份有限公司 | 西达本胺联合r-chop的应用及联合药物 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
US5608108A (en) | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
USRE38506E1 (en) * | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
AU712801B2 (en) | 1995-09-20 | 1999-11-18 | Merck Sharp & Dohme Corp. | Histone deacetylase as target for antiprotozoal agents |
US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
US6387673B1 (en) | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
AUPP505798A0 (en) | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
HUP0103985A2 (hu) | 1998-10-13 | 2002-02-28 | Fujisawa Pharmaceutical Co., Ltd. | Ciklikus tetrapeptid, és annak felhasználása |
WO2000071703A2 (en) | 1999-05-03 | 2000-11-30 | Methylgene Inc. | Inhibition of histone deacetylase |
JP2003509343A (ja) | 1999-09-08 | 2003-03-11 | スローン−ケターリング インスティチュート フォー キャンサー リサーチ | 新規クラスの細胞分化剤およびヒストンデアセチラーゼならびにそれらの使用方法 |
DK1233958T3 (da) | 1999-11-23 | 2011-10-17 | Methylgene Inc | Hæmmere af histondeacetylase |
ATE489360T1 (de) | 2000-03-24 | 2010-12-15 | Methylgene Inc | Inhibitoren der histon-deacetylase |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
AU2001287157A1 (en) * | 2000-09-12 | 2002-03-26 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
AU2001290131B2 (en) | 2000-09-29 | 2007-11-15 | Topotarget Uk Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
AU2002243231A1 (en) * | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
AR035659A1 (es) | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
EP1532244A4 (en) * | 2001-06-14 | 2005-12-14 | Bristol Myers Squibb Co | NEW HISTONIC HUMAN DEACETYLASES |
ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
US20040132643A1 (en) * | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
EP1482962A4 (en) * | 2002-02-15 | 2009-12-23 | Sloan Kettering Inst Cancer | METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX) |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
NZ567758A (en) * | 2002-03-04 | 2009-07-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA) |
US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
EP1501489A4 (en) * | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
JP2006508986A (ja) * | 2002-11-20 | 2006-03-16 | エルラント ゲネ セラペウチクス エルエルシー | ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法 |
EP1613592A4 (en) * | 2003-04-01 | 2008-03-12 | Sloan Kettering Inst Cancer | HYDROXANIC ACID COMPOUNDS AND METHOD FOR THE APPLICATION |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
-
2004
- 2004-08-26 EP EP04782425A patent/EP1663194B1/en active Active
- 2004-08-26 ES ES04782425T patent/ES2345775T3/es active Active
- 2004-08-26 KR KR1020067003748A patent/KR100924737B1/ko not_active IP Right Cessation
- 2004-08-26 CN CN201110072778XA patent/CN102188415A/zh active Pending
- 2004-08-26 BR BRPI0413826-0A patent/BRPI0413826A/pt not_active IP Right Cessation
- 2004-08-26 AT AT04782425T patent/ATE462426T1/de active
- 2004-08-26 EP EP10158245A patent/EP2201947A3/en not_active Withdrawn
- 2004-08-26 DK DK04782425.5T patent/DK1663194T3/da active
- 2004-08-26 WO PCT/US2004/027943 patent/WO2005018578A2/en active IP Right Grant
- 2004-08-26 PT PT04782425T patent/PT1663194E/pt unknown
- 2004-08-26 JP JP2006524891A patent/JP4338734B2/ja not_active Expired - Fee Related
- 2004-08-26 NZ NZ560485A patent/NZ560485A/en not_active IP Right Cessation
- 2004-08-26 AU AU2004266169A patent/AU2004266169B9/en active Active
- 2004-08-26 RU RU2006109467/14A patent/RU2356547C2/ru not_active IP Right Cessation
- 2004-08-26 PL PL379887A patent/PL379887A1/pl unknown
- 2004-08-26 CA CA002535806A patent/CA2535806C/en not_active Expired - Fee Related
- 2004-08-26 PL PL04782425T patent/PL1663194T3/pl unknown
- 2004-08-26 SI SI200431448T patent/SI1663194T1/sl unknown
- 2004-08-26 DE DE602004026321T patent/DE602004026321D1/de active Active
- 2004-08-26 NZ NZ54593504A patent/NZ545935A/xx not_active IP Right Cessation
-
2006
- 2006-02-21 IL IL173846A patent/IL173846A0/en unknown
- 2006-02-23 HR HR20060080A patent/HRP20060080A2/xx not_active Application Discontinuation
- 2006-02-23 MA MA28833A patent/MA28209A1/fr unknown
- 2006-03-23 EC EC2006006452A patent/ECSP066452A/es unknown
- 2006-03-24 NO NO20061348A patent/NO328575B1/no not_active IP Right Cessation
-
2008
- 2008-07-08 US US12/217,843 patent/US20090012175A1/en not_active Abandoned
- 2008-09-11 JP JP2008232889A patent/JP4914411B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066452A (es) | Métodos para el tratamiento del cáncer con inhibidores de hdac | |
WO2005039498A3 (en) | Methods of treating cancer with hdac inhibitors | |
WO2003075839A3 (en) | Methods of inducing terminal differentiation | |
CY1109363T1 (el) | Υδροξαμικες ενωσεις ως θεραπευτικοι παραγοντες | |
DE60321775D1 (de) | Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren | |
EA201500431A1 (ru) | Соединения боронатного эфира и его фармацевтические составы | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
DE602006017728D1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
TW200510392A (en) | Chemical compounds | |
MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. | |
NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
TW200505452A (en) | Chemical compounds | |
UA96794C2 (ru) | Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе | |
CY1110659T1 (el) | Χρησιμοποιηση toy saha για την θεραπευτικη αγωγη μεσοθηλιωματος | |
CY1116274T1 (el) | Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας | |
MX2008008470A (es) | Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas. | |
ATE451340T1 (de) | Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel | |
EA201991188A1 (ru) | Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний | |
EA200600998A1 (ru) | Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза | |
TW200728296A (en) | Chemical compounds | |
SE0203817D0 (sv) | New composition | |
EA200501366A1 (ru) | Лекарственное средство | |
MY136047A (en) | Novel potentiating compounds |